Compare F5 Inc (FFIV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Sana Biotechnology Inc — how do they compare? F5 Inc trades at $415.62 (market cap $23.44B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: F5 Inc is far larger — about 20.7× Sana Biotechnology Inc's market cap, and F5 Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| FFIV | SANA | |
|---|---|---|
Market Cap | $23.44B | $1.13B |
Sector | Technology | Health |
52-Week High | $431.26 | $5.92 |
52-Week Low | $223.99 | $2.68 |
Enterprise Value | $22.08B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $422.95, up 3.16% on the day, near its 52-week high. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. Technical indicators show a bullish trend with support at $411 and resistance at $425. Fundamentals remain solid with revenue growth to $3.09B in 2025 and net income margin of 21.95%.
Outlook is positive given raised revenue guidance and robust cybersecurity demand, but valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and execution challenges in sustaining high growth. Analyst consensus is Moderate Buy with a $430.43 price target, indicating modest upside potential from current levels.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
